The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma

Lluis A. Lopez-Barcons, Junhong Zhang, Gunching Siriwitayawan, Thomas G. Burke, Roman Perez-Soler

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Colorectal carcinoma occurs in 1 of 20 individuals in most developed countries. The relapse after resection with metastatic liver disease is a major cause of death. 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (DB67) has been incorporated into liposomes allowing for intravenous (i.v.) administration. A preclinical efficacy study of liposomal DB67 was performed using the colon carcinoma CT-26 cell line. The therapeutic dose for DB67 and liposomal DB67 was found to be 7 mg/kg per day using the qdx5/1 schedule. The results are compared with those obtained with irinotecan. The treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and volume of primary spleen tumors and the weight and extent of liver metastases than free DB67 or liposomal DB67 administered intraperitoneally, but less effective than irinotecan. When the primary tumor was resected, treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and extent of liver metastases than DB67 or liposomal DB67 administered intraperitoneally, and irinotecan. DB67 showed a higher accumulation in spleen and liver after its i.v. administration in liposomal form compared with its free or liposomal form administered intraperitoneally. DB67 and liposomal DB67 are more effective than irinotecan in the treatment of liver metastases after resection of the primary tumor.

Original languageEnglish (US)
Pages (from-to)457-467
Number of pages11
JournalNeoplasia
Volume6
Issue number5
DOIs
StatePublished - Sep 2004

Fingerprint

irinotecan
Topoisomerase I Inhibitors
Colon
Neoplasm Metastasis
Carcinoma
Liver
Intravenous Administration
Spleen
Weights and Measures
Therapeutics
Tumor Burden
Developed Countries
Liposomes
Liver Diseases
Cause of Death
Colorectal Neoplasms
Neoplasms
Appointments and Schedules
Recurrence
Cell Line

Keywords

  • Colorectal carcinoma
  • CT-26
  • DB67
  • Irinotecan
  • Liposome

ASJC Scopus subject areas

  • Cancer Research

Cite this

The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. / Lopez-Barcons, Lluis A.; Zhang, Junhong; Siriwitayawan, Gunching; Burke, Thomas G.; Perez-Soler, Roman.

In: Neoplasia, Vol. 6, No. 5, 09.2004, p. 457-467.

Research output: Contribution to journalArticle

Lopez-Barcons, Lluis A. ; Zhang, Junhong ; Siriwitayawan, Gunching ; Burke, Thomas G. ; Perez-Soler, Roman. / The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. In: Neoplasia. 2004 ; Vol. 6, No. 5. pp. 457-467.
@article{46aeebf6ae42417fadf2d5b02eeac913,
title = "The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma",
abstract = "Colorectal carcinoma occurs in 1 of 20 individuals in most developed countries. The relapse after resection with metastatic liver disease is a major cause of death. 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (DB67) has been incorporated into liposomes allowing for intravenous (i.v.) administration. A preclinical efficacy study of liposomal DB67 was performed using the colon carcinoma CT-26 cell line. The therapeutic dose for DB67 and liposomal DB67 was found to be 7 mg/kg per day using the qdx5/1 schedule. The results are compared with those obtained with irinotecan. The treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and volume of primary spleen tumors and the weight and extent of liver metastases than free DB67 or liposomal DB67 administered intraperitoneally, but less effective than irinotecan. When the primary tumor was resected, treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and extent of liver metastases than DB67 or liposomal DB67 administered intraperitoneally, and irinotecan. DB67 showed a higher accumulation in spleen and liver after its i.v. administration in liposomal form compared with its free or liposomal form administered intraperitoneally. DB67 and liposomal DB67 are more effective than irinotecan in the treatment of liver metastases after resection of the primary tumor.",
keywords = "Colorectal carcinoma, CT-26, DB67, Irinotecan, Liposome",
author = "Lopez-Barcons, {Lluis A.} and Junhong Zhang and Gunching Siriwitayawan and Burke, {Thomas G.} and Roman Perez-Soler",
year = "2004",
month = "9",
doi = "10.1593/neo.04139",
language = "English (US)",
volume = "6",
pages = "457--467",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma

AU - Lopez-Barcons, Lluis A.

AU - Zhang, Junhong

AU - Siriwitayawan, Gunching

AU - Burke, Thomas G.

AU - Perez-Soler, Roman

PY - 2004/9

Y1 - 2004/9

N2 - Colorectal carcinoma occurs in 1 of 20 individuals in most developed countries. The relapse after resection with metastatic liver disease is a major cause of death. 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (DB67) has been incorporated into liposomes allowing for intravenous (i.v.) administration. A preclinical efficacy study of liposomal DB67 was performed using the colon carcinoma CT-26 cell line. The therapeutic dose for DB67 and liposomal DB67 was found to be 7 mg/kg per day using the qdx5/1 schedule. The results are compared with those obtained with irinotecan. The treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and volume of primary spleen tumors and the weight and extent of liver metastases than free DB67 or liposomal DB67 administered intraperitoneally, but less effective than irinotecan. When the primary tumor was resected, treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and extent of liver metastases than DB67 or liposomal DB67 administered intraperitoneally, and irinotecan. DB67 showed a higher accumulation in spleen and liver after its i.v. administration in liposomal form compared with its free or liposomal form administered intraperitoneally. DB67 and liposomal DB67 are more effective than irinotecan in the treatment of liver metastases after resection of the primary tumor.

AB - Colorectal carcinoma occurs in 1 of 20 individuals in most developed countries. The relapse after resection with metastatic liver disease is a major cause of death. 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (DB67) has been incorporated into liposomes allowing for intravenous (i.v.) administration. A preclinical efficacy study of liposomal DB67 was performed using the colon carcinoma CT-26 cell line. The therapeutic dose for DB67 and liposomal DB67 was found to be 7 mg/kg per day using the qdx5/1 schedule. The results are compared with those obtained with irinotecan. The treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and volume of primary spleen tumors and the weight and extent of liver metastases than free DB67 or liposomal DB67 administered intraperitoneally, but less effective than irinotecan. When the primary tumor was resected, treatment with liposomal DB67 administered intravenously was more effective in reducing the weight and extent of liver metastases than DB67 or liposomal DB67 administered intraperitoneally, and irinotecan. DB67 showed a higher accumulation in spleen and liver after its i.v. administration in liposomal form compared with its free or liposomal form administered intraperitoneally. DB67 and liposomal DB67 are more effective than irinotecan in the treatment of liver metastases after resection of the primary tumor.

KW - Colorectal carcinoma

KW - CT-26

KW - DB67

KW - Irinotecan

KW - Liposome

UR - http://www.scopus.com/inward/record.url?scp=6944255267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944255267&partnerID=8YFLogxK

U2 - 10.1593/neo.04139

DO - 10.1593/neo.04139

M3 - Article

VL - 6

SP - 457

EP - 467

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 5

ER -